We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity.
- Authors
Yang, Minghui; Li, Chunhui; Ye, Guoguo; Shen, Chenguang; Shi, Huiping; Zhong, Liping; Tian, Yuxin; Zhao, Mengyuan; Wu, Pengfei; Hussain, Abid; Zhang, Tian; Yang, Haiyin; Yang, Jun; Weng, Yuhua; Liu, Xinyue; Wang, Zhimin; Gan, Lu; Zhang, Qianyu; Liu, Yingxia; Yang, Ge
- Abstract
Emerging and recurrent infectious diseases caused by human coronaviruses (HCoVs) continue to pose a significant threat to global public health security. In light of this ongoing threat, the development of a broad-spectrum drug to combat HCoVs is an urgently priority. Herein, we report a series of anti-pan-coronavirus ssDNA aptamers screened using Systematic Evolution of Ligands by Exponential Enrichment (SELEX). These aptamers have nanomolar affinity with the nucleocapsid protein (NP) of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and also show excellent binding efficiency to the N proteins of both SARS, MERS, HCoV-OC43 and -NL63 with affinity KD values of 1.31 to 135.36 nM. Such aptamer-based therapeutics exhibited potent antiviral activity against both the authentic SARS-CoV-2 prototype strain and the Omicron variant (BA.5) with EC50 values at 2.00 nM and 41.08 nM, respectively. The protein docking analysis also evidenced that these aptamers exhibit strong affinities for N proteins of pan-coronavirus and other HCoVs (−229E and -HKU1). In conclusion, we have identified six aptamers with a high pan-coronavirus antiviral activity, which could potentially serve as an effective strategy for preventing infections by unknown coronaviruses and addressing the ongoing global health threat.
- Publication
Signal Transduction & Targeted Therapy, 2024, Vol 9, Issue 1, p1
- ISSN
2095-9907
- Publication type
Article
- DOI
10.1038/s41392-024-01748-w